AKTS
Aktis Oncology, Inc. Common stock
NASDAQ: AKTS · HEALTHCARE · BIOTECHNOLOGY
$18.75
+0.16% today
Updated 2026-04-30
Market cap
$1.18B
P/E ratio
—
P/S ratio
180.88x
EPS (TTM)
$-1.21
Dividend yield
—
52W range
$15 – $29
Volume
0.4M
Aktis Oncology, Inc. Common stock (AKTS) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
+36.2%
Last 4 quarters
Revenue YoY growth
-73.4%
Most recent quarter
EPS YoY growth
-49.2%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-1.9%
Last 1 reports
Positive reaction rate
0%
0 of 1 quarters
Largest single-day move
-1.9%
2026-02-25
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-25 | $-0.28 | +75.3% | $20.00 | $19.63 | -1.9% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-1.15 | $-0.28 | +75.3% | $1.87M | — |
| 2025-09-30 | $0.00 | $-16.06 | — | — | — |
| 2024-09-30 | $-0.08 | $-0.04 | +50.0% | $9.03M | +28.9% |
| 2024-03-31 | $-0.12 | $-0.14 | -16.7% | $7.51M | +2.1% |
| 2023-12-31 | $-0.18 | $-0.19 | -5.6% | $7.02M | +19.6% |
| 2023-09-30 | $-0.18 | $-0.27 | -50.0% | $7.00M | +25.8% |
| 2023-03-31 | $-0.21 | $-0.20 | +4.8% | $7.36M | +59.7% |
| 2022-12-31 | $-0.25 | $-0.19 | +24.0% | $5.87M | — |
| 2022-09-30 | $-0.23 | $-0.28 | -21.7% | $5.57M | — |
| 2022-03-31 | $-0.23 | $-0.22 | +4.3% | $4.61M | — |
| 2021-12-31 | $-0.23 | $-0.23 | +0.0% | — | — |
Frequently asked questions
Has Aktis Oncology, Inc. Common stock beaten earnings estimates?
Aktis Oncology, Inc. Common stock has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of +36.2% over the last 3 quarters.
How does AKTS stock react to earnings?
AKTS stock has moved an average of -1.9% in the trading day following earnings over its last 1 reports, with positive reactions in 0% of those quarters.
What is Aktis Oncology, Inc. Common stock's revenue growth rate?
Aktis Oncology, Inc. Common stock reported year-over-year revenue growth of -73.4% in its most recent quarter, with EPS growing -49.2% year-over-year.